• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ABTL0812 enhances antitumor effect of paclitaxel and reverts chemoresistance in triple-negative breast cancer models.

作者信息

Polonio-Alcalá Emma, Solé-Sánchez Sònia, Muñoz-Guardiola Pau, Megías-Roda Elisabet, Perez-Montoyo Héctor, Yeste-Velasco Marc, Alfón Jose, Lizcano Jose Miguel, Domènech Carles, Ruiz-Martínez Santiago, Puig Teresa

机构信息

New Therapeutic Targets Laboratory (TargetsLab)-Oncology Unit, Department of Medical Sciences, University of Girona, Girona, 17003, Spain.

Product, Process and Production Engineering Research Group (GREP), Department of Mechanical Engineering and Industrial Construction, University of Girona, Girona, 17003, Spain.

出版信息

Cancer Commun (Lond). 2022 Jun;42(6):567-571. doi: 10.1002/cac2.12282. Epub 2022 Mar 16.

DOI:10.1002/cac2.12282
PMID:35293148
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9198345/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4c3/9198345/860e2cd71f39/CAC2-42-567-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4c3/9198345/860e2cd71f39/CAC2-42-567-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4c3/9198345/860e2cd71f39/CAC2-42-567-g001.jpg

相似文献

1
ABTL0812 enhances antitumor effect of paclitaxel and reverts chemoresistance in triple-negative breast cancer models.ABTL0812增强了紫杉醇在三阴性乳腺癌模型中的抗肿瘤作用并逆转了化疗耐药性。
Cancer Commun (Lond). 2022 Jun;42(6):567-571. doi: 10.1002/cac2.12282. Epub 2022 Mar 16.
2
Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models.氯喹通过抑制自噬作用防止三阴性乳腺癌模型对 PI3K/AKT 抑制剂产生耐药性，并增强其与紫杉醇联合的抗肿瘤作用。
J Transl Med. 2022 Jun 27;20(1):290. doi: 10.1186/s12967-022-03462-z.
3
Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer.靶向自噬性癌症干细胞以逆转人类三阴性乳腺癌的化疗耐药性。
Oncotarget. 2017 May 23;8(21):35205-35221. doi: 10.18632/oncotarget.16925.
4
High-metastatic triple-negative breast-cancer variants selected in vivo become chemoresistant in vitro.在体内筛选出的高转移性三阴性乳腺癌变体在体外产生化疗耐药性。
In Vitro Cell Dev Biol Anim. 2017 Apr;53(4):285-287. doi: 10.1007/s11626-016-0117-y. Epub 2017 Jan 26.
5
BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.BRCA1-IRIS失活克服三阴性乳腺癌中的紫杉醇耐药性。
Breast Cancer Res. 2015 Jan 13;17(1):5. doi: 10.1186/s13058-014-0512-9.
6
Role of inhibitor of yes-associated protein 1 in triple-negative breast cancer with taxol-based chemoresistance.YAP1 抑制剂在紫杉醇类化疗耐药三阴性乳腺癌中的作用。
Cancer Sci. 2019 Feb;110(2):561-567. doi: 10.1111/cas.13888. Epub 2019 Jan 4.
7
The novel proautophagy anticancer drug ABTL0812 potentiates chemotherapy in adenocarcinoma and squamous nonsmall cell lung cancer.新型自噬促进抗癌药物 ABTL0812 增强腺癌和鳞状非小细胞肺癌的化疗效果。
Int J Cancer. 2020 Aug 15;147(4):1163-1179. doi: 10.1002/ijc.32865. Epub 2020 Feb 6.
8
Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells.SMAC 或 BH3 模拟物对凋亡途径的靶向作用可显著使耐紫杉醇的三阴性乳腺癌细胞敏感化。
Oncotarget. 2017 Jul 11;8(28):45088-45104. doi: 10.18632/oncotarget.15125.
9
Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.靶向三阴性乳腺癌的 EGFR 可增强紫杉醇和西妥昔单抗偶联纳米金刚石纳米复合材料的治疗效果。
Acta Biomater. 2019 Mar 1;86:395-405. doi: 10.1016/j.actbio.2019.01.025. Epub 2019 Jan 16.
10
Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer.通过全基因组整合筛选鉴定出截短的 HDAC9，是三阴性乳腺癌中紫杉醇耐药的关键调节因子。
Theranostics. 2020 Sep 2;10(24):11092-11109. doi: 10.7150/thno.44997. eCollection 2020.

引用本文的文献

1
Near-Infrared Afterglow Imaging-Guided Surgical Resection and Synergistic Photodynamic-Chemo Therapy of Breast Cancer.近红外余辉成像引导下的乳腺癌手术切除及光动力-化疗协同治疗
Adv Sci (Weinh). 2025 Sep;12(33):e03883. doi: 10.1002/advs.202503883. Epub 2025 Jun 10.
2
Novel HSA-PMEMA Nanomicelles Prepared via Site-Specific In Situ Polymerization-Induced Self-Assembly for Improved Intracellular Delivery of Paclitaxel.通过位点特异性原位聚合诱导自组装制备的新型人血清白蛋白-聚甲基丙烯酸甲酯纳米胶束用于改善紫杉醇的细胞内递送
Pharmaceutics. 2025 Mar 1;17(3):316. doi: 10.3390/pharmaceutics17030316.
3
Anticancer effects of ABTL0812, a clinical stage drug inducer of autophagy-mediated cancer cell death, in glioblastoma models.

本文引用的文献

1
The antitumour drug ABTL0812 impairs neuroblastoma growth through endoplasmic reticulum stress-mediated autophagy and apoptosis.抗肿瘤药物 ABTL0812 通过内质网应激介导的自噬和凋亡来抑制神经母细胞瘤的生长。
Cell Death Dis. 2020 Sep 17;11(9):773. doi: 10.1038/s41419-020-02986-w.
2
The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells.抗癌药物 ABTL0812 通过增加癌细胞中二氢神经酰胺水平诱导 ER 应激介导的细胞毒性自噬。
Autophagy. 2021 Jun;17(6):1349-1366. doi: 10.1080/15548627.2020.1761651. Epub 2020 May 25.
3
The novel proautophagy anticancer drug ABTL0812 potentiates chemotherapy in adenocarcinoma and squamous nonsmall cell lung cancer.
ABTL0812（一种处于临床阶段的自噬介导癌细胞死亡诱导药物）在胶质母细胞瘤模型中的抗癌作用。
Front Oncol. 2022 Nov 2;12:943064. doi: 10.3389/fonc.2022.943064. eCollection 2022.
新型自噬促进抗癌药物 ABTL0812 增强腺癌和鳞状非小细胞肺癌的化疗效果。
Int J Cancer. 2020 Aug 15;147(4):1163-1179. doi: 10.1002/ijc.32865. Epub 2020 Feb 6.
4
Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer.新型 TRIB3 介导线粒体自噬抗癌药物 ABLT0812 在子宫内膜癌中的治疗潜力。
Gynecol Oncol. 2019 May;153(2):425-435. doi: 10.1016/j.ygyno.2019.03.002. Epub 2019 Mar 7.
5
A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy.一种新型口服硒嘌呤分子通过诱导细胞静止自噬来抑制三阴性乳腺癌细胞的增殖和转移进展。
Autophagy. 2019 Aug;15(8):1376-1390. doi: 10.1080/15548627.2019.1582951. Epub 2019 Mar 1.
6
Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.三阴性乳腺癌中 PI3K/AKT/mTOR 通路的靶向治疗：综述。
Breast Cancer Res Treat. 2018 Jun;169(3):397-406. doi: 10.1007/s10549-018-4697-y. Epub 2018 Feb 7.
7
Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7/Dox breast cancer cells.奈非那韦针对多种耐药机制，以提高阿霉素在MCF-7/Dox乳腺癌细胞中的疗效。
Biochimie. 2016 May;124:53-64. doi: 10.1016/j.biochi.2016.01.014. Epub 2016 Feb 1.
8
The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase.新型抗肿瘤药物 ABTL0812 通过上调 Tribbles-3 假激酶抑制 Akt/mTORC1 轴。
Clin Cancer Res. 2016 May 15;22(10):2508-19. doi: 10.1158/1078-0432.CCR-15-1808. Epub 2015 Dec 15.
9
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.鉴定人类三阴性乳腺癌亚型和临床前模型以选择靶向治疗药物。
J Clin Invest. 2011 Jul;121(7):2750-67. doi: 10.1172/JCI45014.
10
Triple-negative breast cancer: clinical features and patterns of recurrence.三阴性乳腺癌：临床特征与复发模式
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34. doi: 10.1158/1078-0432.CCR-06-3045.